Ozanimodâ–¼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of ALS ...
Inhaling xenon gas reduced neuroinflammation and brain atrophy while increasing protective neuronal states in mouse models of ...
A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...
Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...
The study found that Xenon gas inhalation suppressed neuroinflammation, reduced brain atrophy, and increased protective ...
Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but ...
Early signs of multiple sclerosis can include blurry vision, muscle weakness, dizziness and fatigue, and unusual tingling or pain sensations. These early warning signs occur because of damage to the ...
About ALS Amyotrophic lateral sclerosis (ALS) is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people ...
Multiple sclerosis (MS) is a chronic condition affecting the central nervous system. Its symptoms range from mild and intermittent to severe and permanently damaging. There’s currently no cure ...
UB-312 is under clinical development by Vaxxinity and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, Phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback